About Nektar
Nektar is a company based in San Francisco (United States) founded in 1990. The company has 61 employees as of December 31, 2024. Nektar has completed 1 acquisition, including Aerogen. Nektar offers products and services including REZPEG, PEG-CSF1, and TNFR-2. Nektar operates in a competitive market with competitors including Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter San Francisco, United States
- Employees 61 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nektar Therapeutics
-
Annual Revenue
$98.43 M (USD)9.22as on Dec 31, 2024
-
Net Profit
-$118.96 M (USD)56.91as on Dec 31, 2024
-
EBITDA
-$128.73 M (USD)0.68as on Dec 31, 2024
-
Latest Funding Round
$30 M (USD), Post-IPO
Mar 04, 2024
-
Investors
Astrazeneca
& 2 more
-
Employee Count
61
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nektar
Nektar is a publicly listed company on the NASDAQ with ticker symbol NKTR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nektar
Nektar offers a comprehensive portfolio of products and services, including REZPEG, PEG-CSF1, and TNFR-2.
Targets immune pathways for autoimmune disorder treatment.
Modulates immune responses for inflammatory conditions.
Advances treatments for chronic inflammatory diseases.
People of Nektar
Unlock access to complete
Unlock access to complete
Leadership Team
30 people
Finance and Accounting
9 people
Software Development Team
9 people
Product Management Team
7 people
Senior Team
6 people
Legal and Compliance
5 people
Human Resources and Administration
5 people
Scientist Team
5 people
Unlock access to complete
Funding Insights of Nektar
Investors in Nektar
Nektar has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, BB Biotech and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Pharmaceutical and biologics products are developed and distributed worldwide.
|
Locked | Locked | Locked |
Investor details for Nektar
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nektar
Nektar has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Aerogen.
Investment portfolio details for Nektar
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vibrating mesh nebulizers are manufactured for aerosol drug delivery.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Nektar
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nektar
Detailed financials for Nektar
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nektar Comparisons
Peer comparison for Nektar
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nektar
Nektar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Nektar
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nektar
Complete news archive for Nektar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nektar
Nektar was founded in 1990 and raised its 1st funding round 21 years after it was founded.
Nektar is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
As of Dec 31, 2024, the latest employee count at Nektar is 61.
Annual revenue of Nektar is $98.43M as on Dec 31, 2024.
Founded in 1990 and based in San Francisco, United States, the company operates in the biotechnology sector. Drug candidates are developed through PEGylation and polymer conjugate technologies to address cancer, pain, anti-infectives, anti-viral, and immunological conditions. The pipeline features NKTR-358 for autoimmune diseases, Bempegaldesleukin for viral indications, and various oncology programs.
Nektar's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Nektar offers REZPEG, PEG-CSF1, and TNFR-2.
Yes, Nektar is publicly traded on NASDAQ under the ticker symbol NKTR.
Nektar has made 1 acquisition, including Aerogen.
Nektar has 3 investors. Key investors include Astrazeneca, BB Biotech, and NEA.
The ticker symbol of Nektar is NKTR on NASDAQ.